Loss of FHIT expression in transitional cell carcinoma of the urinary bladder

American Journal of Pathology

Volumn 156, Issue 2, 2000, Pages 419-424

  Baffa, Raffaele ^a   Gomella, Leonard G ^a   Vecchione, Andrea ^a   Bassi, Pierfrancesco ^b   Mimori, Koshi ^a   Sedor, John ^a   Calviello, Coleen M ^a   Gardiman, Marina ^b   Minimo, Corrado ^a   Strup, Stephen E ^a   McCue, Peter A ^a   Kovatich, Albert J ^a   Pagano, Francesco ^b   Huebner, Kay ^a   Croce, Carlo M ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLADDER CARCINOMA; CANCER CELL CULTURE; CHROMOSOME 3P; GENE DELETION; GENE LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSITIONAL CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 0033882791     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64745-1     Document Type: Article

References (35)

1. Current management of invasive and metastatic transitional cell carcinoma of the bladder
2. Cancer statistics
3. TNM classification of malignant tumors
4. Bladder cancer epidemiology and pathogenesis
5. Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinoma of the bladder
6. Molecular genetic alteration in superficial and locally advanced human bladder cancer
7. Role of chromosome 9 in human bladder cancer
8. Evidence for two bladder cancer suppressor loci on chromosome 9 in human bladder cancer
9. Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinomas
10. Loss of RB protein expression in primary bladder cancer correlated with loss of heterozygosity at RB locus and tumor progression
11. Chromosome 3 allelic losses, and microsatellite alteration in transitional cell carcinoma of the urinary bladder
12. Minimal deletion of 3p13-14.2 associated with immortalization of human uroepithelial cells
13. Deletion of chromosomal imbalance in transitional cell carcinoma of the bladder by comparative genomic hybridization
14. The FHIT gene spanning the chromosome 3p14.2 fragile site, and renal carcinoma-associated t(3; 8) breakpoint, is abnormal in digestive tract cancers
15. FHIT a putative tumor suppressor in humans, is a dinucleoside 5',5'-P1, P3-triphosphate hydrolase
16. FRA3B extends over a broad region and contains a spontaneous HPV 16 integration site: Direct evidence for the coincidence of viral integration site and fragile sites
17. Direct cloning of DNA sequences from the common fragile site region at chromosome band 3p14.2
18. Potential gastrointestinal tumor suppressor locus at the 3p14.2 FRA3B site identified by homozygous deletions in tumor cell lines
19. Structure and expression of the human FHIT gene in norms and tumor cells
20. Absence or reduction of FHIT expression in most clear cell renal carcinoma
21. Ha-ras oncogenes are activated by somatic alterations in human urinary tract tumors
22. Expression of mutant p53, c-erb-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder
23. Hereditary renal-cell carcinoma associated with chromosomal translocation
24. Sequence of the FRA3B common fragile region: Implications for the mechanism of FHIT deletion
25. Cancer-specific chromosome alterations in the constitutive fragile region FRA3B
26. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors
27. The FHIT gene at 3p14.2 is abnormal in lung cancer
28. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations
29. Molecular analysis of the FHIT gene at 3p14.2 in lung cancer cell lines
30. Loss of FHIT expression in gastric carcinoma
31. Frequent breakpoints in the 3p14.2 fragile site FRA3B in pancreatic tumors
32. The FHIT gene is expressed in pancreatic ductular cells and is altered in pancreatic cancers
33. FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease
34. Loss of FHIT function in lung cancer and preinvasive bronchial lesions
35. Fhit expression in gastric adenocarcinoma: Correlation with disease stage and survival